Overactive bladder (OAB) is a group of symptoms that are not usually life-threatening but can significantly decrease productivity and quality of life. The condition is characterized by the sudden need ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

Female bladder cancer patients undergoing bladder-sparing therapies often experience minimal disruption to sexual health compared to those undergoing cystectomy. The study underscores the need for ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

In May, Gilead Sciences announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial.

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead ...

But that drug is primarily used to treat blood cancers like lymphoma, while Trodelvy is aimed at a variety of solid tumors. The setback in bladder cancer is a small disappointment, representing less ...

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more common disease: bladder cancer. In a phase 1 trial in patients with non ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...